News tagged with avastin
US panel rejects Avastin for breast cancer use
An expert panel urged the US Food and Drug Administration on Wednesday to strip the Roche-made drug Avastin of its label for use against breast cancer because it is neither safe nor effective.
Medicine & Health / Medications
Jun 29, 2011 |
not rated yet |
0
FDA panel: Revoke drug's breast cancer approval
(AP) -- A panel of cancer experts has ruled for a second time that Avastin, the best-selling cancer drug in the world, should no longer be used in breast cancer patients, clearing the way for the government to remove its ...
Medicine & Health / Medications
Jun 28, 2011 |
not rated yet |
0
Hearing may be end of road for breast cancer drug
(AP) -- The best-selling cancer drug in the world comes under federal scrutiny once again this week, as drugmaker Roche makes a last-ditch effort to keep Avastin approved for breast cancer, despite evidence ...
Medicine & Health / Medications
Jun 27, 2011 |
5 / 5 (1) |
0
FDA panel unanimously backs Regeneron eye drug
(AP) -- A panel of federal health experts voted unanimously in favor of a new eye drug from Regeneron, bringing the company one step closer to competing against a blockbuster Roche drug that currently dominates the market.
Medicine & Health / Medications
Jun 17, 2011 |
not rated yet |
0
Analysis details Avastin's rare fatal side effects
(AP) -- A new analysis raises fresh questions about the risks of the blockbuster cancer drug Avastin, suggesting the chance of dying from side effects linked to it is higher than the risk for patients on chemotherapy alone.
Medicine & Health / Medications
Feb 01, 2011 |
not rated yet |
1
Conversion of brain tumor cells into blood vessels thwarts treatment efforts
Glioblastoma, the most common and lethal form of brain cancer and the disease that killed Massachusetts Senator Ted Kennedy, resists nearly all treatment efforts, even when attacked simultaneously on several ...
Jan 24, 2011 |
5 / 5 (7) |
1
|
FDA: Avastin should not be used for breast cancer (Update)
(AP) -- Federal health authorities are recommending the blockbuster drug Avastin no longer be used to treat breast cancer, saying recent studies failed to show the drug's original promise to help slow the disease.
Dec 16, 2010 |
not rated yet |
1
Researchers find no difference in drugs for macular degeneration
Researchers from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) ...
Medicine & Health / Medications
Oct 01, 2010 |
not rated yet |
0
$93,000 cancer drug: How much is a life worth?
Cancer patients, brace yourselves. Many new drug treatments cost nearly $100,000 a year, sparking fresh debate about how much a few months more of life is worth.
Sep 26, 2010 |
5 / 5 (3) |
6
Experts veto Avastin as a breast cancer treatment
(AP) -- A panel of cancer experts said Tuesday that the government should remove its endorsement of Roche's drug Avastin for breast cancer, after follow-up studies failed to show benefits for patients.
Medicine & Health / Medications
Jul 20, 2010 |
not rated yet |
0
Overcoming ovarian cancer
(PhysOrg.com) -- UCI's gynecologic oncology group forges what is being called the largest breakthrough for treating ovarian cancer in more than a decade.
Jul 06, 2010 |
not rated yet |
0
Cancer drug Avastin may cause kidney damage, study finds
A widely prescribed cancer drug noted for its ability to choke off blood vessels that help tumors grow can cause significant kidney damage in some patients, a team of Long Island scientists has found.
Medicine & Health / Medications
Jun 25, 2010 |
5 / 5 (3) |
1
Inexpensive drug to stop sight loss shown to be effective
An inexpensive, but unlicensed drug to help prevent severe sight loss in older people has been shown to be safe and effective, finds a study published in the British Medical Journal today.
Medicine & Health / Medications
Jun 10, 2010 |
4.3 / 5 (4) |
0
Researchers optimistic in cancer fight, as disease spreads
Medical researchers are posting optimism in the long fight against cancer as advances were unveiled to combat the disease that continues to rise and remains the second biggest killer in the world.
Jun 08, 2010 |
5 / 5 (2) |
0
New treatment regimen shown effective against advanced ovarian cancer
Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards ...
Jun 06, 2010 |
not rated yet |
0
Bevacizumab
Bevacizumab (trade name Avastin, Genentech/Roche) is a monoclonal antibody that recognises all vascular endothelial growth factor (VEGF) isoforms. It is used in the treatment of cancer, where it inhibits tumor growth by blocking the formation of new blood vessels (angiogenesis). Bevacizumab was the first clinically available angiogenesis inhibitor in the United States.
Bevacizumab is currently approved by the U.S. Food and Drug Administration (FDA) for cancers that are metastatic (have spread to other parts of the body). It received its first approval in 2004 was for combination use with standard chemotherapy for metastatic colon cancer and non-small cell lung cancer. In 2008, it was approved by the FDA for use in metastatic breast cancer, a decision that generated some controversy as it went against the recommendation of its advisory panel, who objected because it only slowed tumor growth but failed to extend survival.
Clinical studies are underway in non-metastatic breast cancer, renal cell carcinoma, glioblastoma multiforme, ovarian cancer, castrate-resistant (formally called hormone refractory) prostate cancer, non-metastatic unresectable liver cancer and metastatic or unresectable locally advanced pancreatic cancer. A study released in April 2009 found that bevacizumab is not effective at preventing recurrences of non-metastatic colon cancer following surgery. In May 2009, it received FDA approval for treatment of reoccurring Glioblastoma Multiforme, while treatment for initial growth is still in phase III clinical trial.
For more information about Bevacizumab, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
